-
公开(公告)号：EP1309317B1
公开(公告)日：2006-03-15
申请号：EP01970353.7
申请日：2001-08-15
申请人： Pfizer Limited
CPC分类号： A61K9/2054 , A61K9/2009 , A61K9/485 , A61K9/4866 , A61K31/4422
摘要： A new pharmaceutical composition (A) contains an effective amount of amlodipine maleate (I) and one or more auxiliaries (II), and has a pH of 5.5-7.0 (preferably 6.0-7.0).
-
公开(公告)号：EP1309556B1
公开(公告)日：2004-11-24
申请号：EP01974982.9
申请日：2001-08-15
申请人： Pfizer Limited
发明人： LEMMENS, Jacobus, Maria , PETERS, Theodorus, Hendricus, Antonius , BENNEKER, Franciscus, Bernardus, Gemma , PICHA, Frantisek
IPC分类号： C07D211/90 , A61K31/44 , A61P9/10
CPC分类号： A61K31/4422
摘要： Amlodipine fumarate salt compounds are useful as calcium channel blockers and in treating or preventing angina or hypertension. The fumarate salts avoid the formation of certain potential impurities that have been found to be associated with amlodipine maleate.
摘要翻译： 氨氯地平富马酸盐化合物可用作钙通道阻滞剂并用于治疗或预防心绞痛或高血压。 富马酸盐避免了已经发现与马来酸氨氯地平有关的某些潜在杂质的形成。
-
3.发明公开REFERENCE STANDARDS AND PROCESSES FOR DETERMINING THE PURITY OR STABILITY OF AMLODIPINE MALEATE 审中-公开参考标准和方法用于确定马来酸氨氯地平的纯度和稳定性
公开(公告)号：EP1346214A2
公开(公告)日：2003-09-24
申请号：EP01972795.7
申请日：2001-08-15
申请人： Pfizer Limited
发明人： PICHA, Frantisek , BAKKER, Petrus, Franciscus, Antonius , PETERS, Theodorus, Hendricus, Antonius , LEMMENS, Jacobus, Maria
IPC分类号： G01N33/15 , G01N30/90 , C07D211/90
CPC分类号： G01N33/94 , G01N24/08 , G01N30/90 , G01N2030/625 , G01N2030/8813 , G01N2030/8872 , Y10T436/145555 , Y10T436/25125 , Y10T436/25375
摘要： Amlodipine aspartate and amlodipine maleamide are used as reference standards or markers in determining the purity of amlodipine maleate substances and products.
-
公开(公告)号：EP1355632A1
公开(公告)日：2003-10-29
申请号：EP01995820.6
申请日：2001-12-31
申请人： Pfizer Limited
发明人： PETERS, Theodorus, Hendricus, Antonius , BENNEKER, Franciscus, Bernardus, Gemma , LEMMENS, Jacobus, Maria , KELTJENS, Rolf
CPC分类号： C07D209/48 , A61K9/2009 , A61K9/2054 , A61K9/2059 , A61K9/4866 , A61K31/44
摘要： Amlodipine free base can be formulated into a convenient oral dosage form, especially a tablet, without excessive stickiness or tablet punch residue. The amlodipine free base can be crystalline Form I or a novel Form II. Methods of making and using the amlodipine free base are set forth.
-
公开(公告)号：EP1355632B1
公开(公告)日：2007-01-10
申请号：EP01995820.6
申请日：2001-12-31
申请人： Pfizer Limited
发明人： PETERS, Theodorus, Hendricus, Antonius , BENNEKER, Franciscus, Bernardus, Gemma , LEMMENS, Jacobus, Maria , KELTJENS, Rolf
CPC分类号： C07D209/48 , A61K9/2009 , A61K9/2054 , A61K9/2059 , A61K9/4866 , A61K31/44
摘要： Amlodipine free base can be formulated into a convenient oral dosage form, especially a tablet, without excessive stickiness or tablet punch residue. The amlodipine free base can be crystalline Form I or a novel Form II. Methods of making and using the amlodipine free base are set forth.
-
-
-
-
搜索结果
5 条记录 (耗时 0.01 秒)
